๎
๎ผ
๎
Takeda Pharmaceutical Co Ltd
TAK14.500USD
+0.280+1.97%
์ข
๊ฐย 11/25, 16:00๏ผET๏ผ์์ธ๋ 15๋ถ ์ง์ฐ๋ฉ๋๋ค
45.81B์๊ฐ์ด์ก
1.38P/E TTM
๎
์์ธํ ๋ด์ฉ์ Takeda Pharmaceutical Co Ltd ํ์ฌ
Takeda Pharmaceutical Co Ltd is a Japan-based company mainly engaged in the research and development, manufacture, sale and licensing of pharmaceuticals. The Company focuses on the main business areas of gastrointestinal diseases, rare diseases, plasma derivatives (immune diseases), oncology (cancer), and neuroscience (neuropsychiatric diseases). The Company focuses on three research and development areas: innovative biopharmaceuticals with the focus on gastrointestinal and inflammatory diseases, neuroscience, and oncology, plus plasma derivatives and vaccines. Most of the pharmaceuticals treat rare diseases in the focus disease areas and the plasma derivatives area. The Company operates in Japan, the United States, Europe, and China.
Takeda Pharmaceutical Co Ltd ์ ๋ณด
๎์ข
๋ชฉ ์ฝ๋ TAK
ํ์ฌ ์ด๋ฆTakeda Pharmaceutical Co Ltd
์์ฅ์ผMay 16, 1949
CEOMr. Christophe Weber
์ง์ ์47455
์ ํDepository Receipt
ํ๊ณ ์ฐ๋ ์ข
๋ฃMay 16
์ฃผ์4F
๋์CHUO-KU
์ฆ๊ถ ๊ฑฐ๋์NYSE Consolidated
๊ตญ๊ฐJapan
์ฐํธ ๋ฒํธ103-8668
์ ํ81332782111
์น์ฌ์ดํธhttps://www.takeda.com/
์ข
๋ชฉ ์ฝ๋ TAK
์์ฅ์ผMay 16, 1949
CEOMr. Christophe Weber
Takeda Pharmaceutical Co Ltd์ ํ์ฌ ์์์ง
๎์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
๋ ๋ณด๊ธฐ
์ด๋ฆ
์ด๋ฆ/์ง์
์ง์
์ฃผ์ ๋ณด์
๋ณ๋
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
์์ต ๋ถ์
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Oct 6
ํตํ: USD๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Oct 6
FY2026Q1
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
์ฌ์
๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
๊ธฐํ
62.70B
5.67%
์ง์ญ๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
United States
546.70B
49.40%
Europe And Canada (Country)
262.30B
23.70%
Japan
108.00B
9.76%
Latin America
57.60B
5.20%
China (Country)
43.20B
3.90%
๊ธฐํ
88.90B
8.03%
์ฌ์
๋ณ
์ง์ญ๋ณ
์ฌ์
๋ณUSD
์ด๋ฆ
์์ต
๋น์จ
Gastrointestinal diseases
339.30B
30.66%
Plasma derivatives
260.90B
23.57%
Rare diseases
196.40B
17.75%
Oncology
138.80B
12.54%
Neuroscience
108.60B
9.81%
๊ธฐํ
62.70B
5.67%
์ฃผ์ ๋ณด์ ํต๊ณ
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
๋ง์ง๋ง ์
๋ฐ์ดํธ: Mon, Nov 17
์ฃผ์ฃผ
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
๊ธฐํ
98.94%
์ฃผ์ฃผ
์ฃผ์ฃผ
๋น์จ
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
UBS Financial Services, Inc.
0.19%
Fidelity Management & Research Company LLC
0.13%
Brandes Investment Partners, L.P.
0.12%
๊ธฐํ
98.94%
์ฃผ์ฃผ ์ ํ
์ฃผ์ฃผ
๋น์จ
Investment Advisor
1.85%
Hedge Fund
0.32%
Investment Advisor/Hedge Fund
0.32%
Research Firm
0.21%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
๊ธฐํ
97.26%
๊ธฐ๊ด ์ฃผ์ ๋ณด์
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ง์ง๋ง ์
๋ฐ์ดํธ: Wed, Oct 1
๋ณด๊ณ ๊ธฐ๊ฐ
๊ธฐ๊ด ์
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
2025Q3
606
78.67M
2.49%
-1.76M
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
๋ ๋ณด๊ธฐ
์ฃผ์ฃผ ํ๋
๎์ด๋ฆ
๋ณด์ ์ฃผ์
๋น์จ
๋ณ๋
Chg %
๋ ์ง
Capital Research Global Investors
13.30M
0.42%
+94.57K
+0.72%
Jun 30, 2025
Parametric Portfolio Associates LLC
5.97M
0.19%
+676.71K
+12.78%
Jun 30, 2025
UBS Financial Services, Inc.
3.98M
0.13%
+2.28M
+133.74%
Jun 30, 2025
Fidelity Management & Research Company LLC
4.08M
0.13%
+275.19K
+7.23%
Jun 30, 2025
Brandes Investment Partners, L.P.
3.71M
0.12%
+208.14K
+5.94%
Jun 30, 2025
Renaissance Technologies LLC
3.30M
0.1%
+141.50K
+4.48%
Jun 30, 2025
Goldman Sachs Asset Management, L.P.
2.85M
0.09%
-44.41K
-1.53%
Jun 30, 2025
Aperio Group, LLC
3.20M
0.1%
+574.34K
+21.83%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
1.22M
0.04%
-181.77K
-12.98%
Jun 30, 2025
๋ ๋ณด๊ธฐ
๊ด๋ จ ETF
๎๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Nov 6
๋ง์ง๋ง ์
๋ฐ์ดํธ: Thu, Nov 6
์ด๋ฆ
๋น์จ
VanEck Pharmaceutical ETF
2.61%
SGI Enhanced Global Income ETF
0.96%
Adasina Social Justice All Cap Global ETF
0.53%
First Trust Value Line Dividend Index Fund
0.4%
ActivePassive International Equity ETF
0.34%
Avantis International Equity ETF
0.06%
Avantis Responsible International Equity ETF
0.06%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Invesco Zacks Multi-Asset Income ETF
0%
๋ ๋ณด๊ธฐ
VanEck Pharmaceutical ETF
๋น์จ2.61%
SGI Enhanced Global Income ETF
๋น์จ0.96%
Adasina Social Justice All Cap Global ETF
๋น์จ0.53%
First Trust Value Line Dividend Index Fund
๋น์จ0.4%
ActivePassive International Equity ETF
๋น์จ0.34%
Avantis International Equity ETF
๋น์จ0.06%
Avantis Responsible International Equity ETF
๋น์จ0.06%
Roundhill GLP-1 & Weight Loss ETF
๋น์จ0%
DFA Dimensional International Core Equity 2 ETF
๋น์จ0%
Invesco Zacks Multi-Asset Income ETF
๋น์จ0%
์ฃผ์ ๋ฐฐ๋น๊ธ
๎์ง๋ 5๋
๋์ ์ด
1.44T
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.
๋ ์ง
๋ฐฐ๋น๊ธ
๊ธฐ์ค์ผ
์ง๊ธ์ผ
๋ฐฐ๋น๋ฝ์ผ
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
์ฃผ์ ๋ถํ
๎๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
๋ ์ง
์ ํ
๋น์จ
๋ฐ์ดํฐ ์์
์์ฃผ ๋ฌป๋ ์ง๋ฌธ
Takeda Pharmaceutical Co Ltd์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋๊ตฌ์ธ๊ฐ์?
๎Takeda Pharmaceutical Co Ltd์ ์์ 5๋ ์ฃผ์ฃผ๋ ๋ค์๊ณผ ๊ฐ์ต๋๋ค:
Capital Research Global Investors๋ 13.30M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.42%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Parametric Portfolio Associates LLC๋ 5.97M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.19%๋ฅผ ์ฐจ์งํฉ๋๋ค.
UBS Financial Services, Inc.๋ 3.98M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.13%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Fidelity Management & Research Company LLC๋ 4.08M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.13%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Brandes Investment Partners, L.P.๋ 3.71M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.12%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Capital Research Global Investors๋ 13.30M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.42%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Parametric Portfolio Associates LLC๋ 5.97M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.19%๋ฅผ ์ฐจ์งํฉ๋๋ค.
UBS Financial Services, Inc.๋ 3.98M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.13%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Fidelity Management & Research Company LLC๋ 4.08M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.13%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Brandes Investment Partners, L.P.๋ 3.71M์ฃผ์ ์ฃผ์์ ๋ณด์ ํ๊ณ ์์ผ๋ฉฐ, ์ ์ฒด ์ฃผ์์ 0.12%๋ฅผ ์ฐจ์งํฉ๋๋ค.
Takeda Pharmaceutical Co Ltd์ ์์ 3๋ ์ฃผ์ฃผ ์ ํ์ ๋ฌด์์ธ๊ฐ์?
๎Takeda Pharmaceutical Co Ltd์ ์ฃผ์ ์ฃผ์ฃผ ์ ํ ์์ 3๊ฐ์ง๋
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.์ ๋๋ค.
Capital Research Global Investors
Parametric Portfolio Associates LLC
UBS Financial Services, Inc.์ ๋๋ค.
Takeda Pharmaceutical Co Ltd(TAK)์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ๋ช ๊ฐ์ ๋๊น?
๎2025Q3 ๊ธฐ์ค์ผ๋ก, Takeda Pharmaceutical Co Ltd์ ์ฃผ์์ ๋ณด์ ํ ๊ธฐ๊ด์ ์ด 606๊ณณ์ด๋ฉฐ, ์ด๋ค์ด ๋ณด์ ํ ์ฃผ์์ ์ด ๊ฐ์น๋ ์ฝ 78.67M๋ก ์ ์ฒด ๋ฐํ ์ฃผ์์ 2.49%๋ฅผ ์ฐจ์งํฉ๋๋ค. ์ด๋ 2025Q2 ๋๋น 0.19% ์ฆ๊ฐํ ์์น์
๋๋ค.
Takeda Pharmaceutical Co Ltd์ ์ต๋ ์์ต์์ ๋ฌด์์ธ๊ฐ์?
๎FY2026Q1 ๊ธฐ์ค, Takeda Pharmaceutical Co Ltd์ Gastrointestinal diseases ๋ถ๋ฌธ์ด ๊ฐ์ฅ ๋์ ๋งค์ถ์ ๊ธฐ๋กํ์ผ๋ฉฐ, ๊ธ์ก์ 339.30B๋ก ์ ์ฒด ๋งค์ถ์ 30.66%๋ฅผ ์ฐจ์งํ์ต๋๋ค.
